AAA
KRYS icon

Affinity Asset Advisors’s Krystal Biotech KRYS Stock Holding History

Affinity Asset Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,746
Closed -$4.76M – 114
2024
Q1 		$4.76M Buy
26,746
+1,746
+7% +$243K 0.59% 51
2023
Q4 		$3.1M Sell
25,000
-32,500
-57% -$3.6M 0.57% 46
2023
Q3 		$6.67M Buy
+57,500
New +$7.02M 1.88% 18

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Affinity Asset Advisors's KRYS Position: Q2 2024 in Review

Affinity Asset Advisors sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 26,746 shares — an estimated $4.76M sold.

Affinity Asset Advisors first reported a position in KRYS in Q3 2023 and held it in 3 quarters. The position peaked at $6.67M in Q3 2023. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

  • Affinity Asset Advisors reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 26,746 Krystal Biotech shares in Q2 2024, an estimated $4.76M.
  • Affinity Asset Advisors first reported a position in Krystal Biotech in Q3 2023 and held it in 3 quarters.
  • Affinity Asset Advisors's Krystal Biotech position peaked at $6.67M in Q3 2023.
  • 245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.